Maintenance Therapy in Bipolar Disorder:
Applying Chronic Disease Management Principles
An Internet CME-Certified Monograph
February 2009
Sponsorship and Support
Sponsored by Veritas Institute for Medical Education, Inc. Supported by an educational
grant from Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. administered
by Ortho-McNeil Janssen Scientific Affairs, LLC.
Method of Participation
Read this monograph, complete the CME Activity Evaluation and Request for Credit
Form online, and receive your statement of credit immediately. Print your statement
of credit. This activity is provided free of charge to participants.
Intended Audience
Psychiatrists
Effective Dates
February 2009 to March 31, 2010
Estimated Time to Complete
2 hours (120 minutes)
Accreditation Statement
Veritas Institute for Medical Education, Inc. is accredited by the Accreditation
Council for Continuing Medical Education to provide continuing medical education
for physicians.
Designation of Credit
Veritas Institute for Medical Education, Inc. designates this educational activity
for a maximum of 2.0 AMA PRA Category 1 CreditsTM. Physicians
should only claim credit commensurate with the extent of their participation in
the activity.
Financial Disclosure Summary
In accordance with the ACCME’s Standards for Commercial Support, all CME providers
are required to disclose to the activity audience the relevant financial relationships
of the planners, teachers, and authors involved in the development of CME content.
An individual has a relevant financial relationship if he or she has a financial
relationship in any amount occurring in the last 12 months with a commercial interest
whose products or services are discussed in the CME activity content over which
the individual has control. Disclosures are as follows:
Andrea Fagiolini, MD: Bristol Myers Squibb (consultant, speakers bureau),
Pfizer (consultant, speakers bureau).
Roger S. McIntyre, MD, FRCPC: AstraZeneca Pharmaceuticals LP (consultant,
speakers bureau), Biovail Pharmaceuticals (consultant, speakers bureau), Bristol-Myers
Squibb Company (consultant, speakers bureau), France Foundation (consultant, speakers
bureau), GlaxoSmithKline (consultant), Janssen-Ortho-McNeil (consultant, speakers
bureau), Eli Lilly and Company (consultant, speakers bureau, grant/research support),
H. Lundbeck A/S (consultant, speakers bureau), Organon (consultant), Pfizer Inc
(consultant), Shire (consultant), Solvay/Wyeth (consultant, speakers bureau).
The staff of Veritas Institute for Medical Education, Inc. has nothing to disclose.
Off-Label/Investigational Uses of Drugs
Participants are advised that this CME activity will contain references to the unlabeled/unapproved/investigational
uses of drugs to treat patients with bipolar disorder.
Disclaimer
The opinions expressed in this activity are those of the faculty and do not necessarily
reflect those of Veritas Institute for Medical Education, Inc. or Janssen, Division
of Ortho-McNeil-Janssen Pharmaceuticals Inc. administered by Ortho-McNeil Janssen
Scientific Affairs, LLC. Please consult the appropriate package insert for full
prescribing information on all drug therapies discussed.
Editorial Board
Editor
Andrea Fagiolini, MD
Associate Professor, Psychiatry
Western Psychiatric Institute and Clinic
University of Pittsburgh School of Medicine
Pittsburgh, Pennsylvania
Faculty Reviewer
Roger S. McIntyre, MD, FRCPC
Associate Professor, Psychiatry and Pharmacology
University of Toronto
Head, Mood Disorders Psychopharmacology Unit
University Health Network
Toronto, Ontario, Canada
Learning Objectives
1. You will be able to apply psychosocial interventions to maximize functional outcomes
and prevent recurrence, relapse, and suicide in patients with bipolar disorder.
2. You will be better able to individualize evidence- and guideline-based pharmacologic
regimens to address syndromal and subsyndromal disease manifestations during the
maintenance phase in patients with bipolar disorder.
|